The Pruritus Therapeutics Market size was valued at USD million in 2021 and is estimated to reach USD million by 2029, growing at a CAGR of 6.1% during the forecast period (2022-2029).
Pruritus, or itch, is commonly related to primary skin issues inclusive of atopic dermatitis, urticaria, psoriasis, Masto cytosis, and dermatitis herpetiformis, amongst others. Ordinary itching normally paperwork the prognosis of a major dermatologic sickness.
Several pores and skin diseases associated with pruritus, together with renal pruritus, hematologic pruritus, cholestatic pruritus, idiopathic generalized pruritus, pruritus related to malignancy, and endocrine pruritus.
Increased ions which include calcium, phosphate, and magnesium are found in pruritic sufferers’ skin. Severe pruritus ends in scratching that reasons secondary pores and skin troubles such as eczematisation, dryness, infection, excoriation, Contact allergy, and lichenification.
To Download free sample @ Click Here
The improvement of recent therapeutics for pruritus is forcing international market increase.
The improvement of new centered cures for specific pruritus is driving the boom of the global pruritus therapeutics marketplace. For instance, the development of Duplimab, which is a monoclonal antibody that mainly goals interleukin-four receptors which are worried inside the progression of the inflammatory response with those other novel therapeutics, for instance, Crisaborole 2% ointment and others are within the pipeline of fundamental key market gamers for topical medicinal drug including the Janus kinase inhibitors. Furthermore, the approval of these newly developed therapeutics via specific regulatory our bodies propels the market closer to boom. For instance, in June 2022, Dupixent (Duplimab), advanced by way of Sanofi, is the primary biologics medicine established via the US Food and Drug Administration to treat slight to intense dermatitis in kids aged 6 months to 5 years. These market occasions and the development of latest therapeutics are fueling the marketplace growth globally.
By Disease Type
- Atopic Dermatitis
- Allergic Contact Dermatitis
By Route of Administration
By Drug Class
- Local Anesthetics
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
The pruritus therapeutics market is competitive, with few major players competing to gain market share. Some major players in the global pruritus therapeutics market include Allergan Inc., Amgen Inc., Astellas Pharma Inc., CARA Therapeutics, Novartis AG, Teva Pharmaceutical Industries Ltd, Pfizer, Sanofi, GlaxoSmithKline, Merck, among others.
The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations contributing to the global Pruritus Therapeutics market’s growth. For instance, in January 2022, Pfizer acquired U.S.FDA approval for its Cibinqo (Adrocitinib), an oral once-a-day Janus kinase inhibitor for treating adults suffering from dermatitis. Also, in April 2022, Leo Pharma presented its interim long-term efficacy data for Adbry. Such incidences create a competitive environment in the Pruritus Therapeutics market.
Company Name: DataM Intelligence
Contact Person: Sai
Email: Send Email
Phone: +1 877 441 4866
Country: United States